Daniel Teper

Daniel Teper

Company: Cytovia Therapeutics

Job title: Co-Founder & Chief Executive Officer


Enhancing the Cytotoxic Anti-Tumor Activity of iNK Cell Therapy Using a Flex-NK™ Cell Engager 4:30 pm

Flex NK Cell Engager antibodies redirect NK cells to kill target tumor cells Flex NK cell Engager antibodies enhance the cytotoxicity of PBNK cells as well as iPSC derived NK cells (iNKs) Pre-clinical data supports initiation of clinical trials in both hematological malignancies and solid tumorsRead more

day: Day 1 Track 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.